ALZN
What one share of Alzamend Neuro holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”).
Alzamend Neuro’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-07-31; the balance sheet is as of 2026-07-31.
| Profit | −$2.31 |
|---|---|
| Cash and investments | $1.57 |
| Book value | $1.20 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$9.00 | — | −$4.94 | — | $1.90 |
| 2021 | — | −$10.42 | — | −$5.60 | — | $4.48 |
| 2022 | — | −$20.81 | — | −$11.14 | — | $20.98 |
| 2023 | — | −$22.89 | — | −$13.73 | — | $4.71 |
| 2024 | — | −$134.11 | — | −$111.49 | — | −$33.94 |
| 2025 | — | −$11.32 | — | −$14.57 | — | $5.10 |
| 2026 | — | −$2.63 | — | −$2.42 | — | $0.17 |